Open-Angle Glaucoma

A large study of patients with primary open-angle glaucoma identified 44 new gene loci linked to glaucoma and confirmed 83 previously reported gene loci, which may improve diagnosis and treatment of glaucoma using genetic information.

Patients with glaucoma who displayed an early treatment response to a 10 µg bimatoprost implant and experienced greater than 20% IOP lowering at 12 weeks had significantly greater odds of a long-term IOP response, according to a speaker.

Patients treated with Vyzulta for open-angle glaucoma and ocular hypertension had significantly better outcomes compared with most beta-blockers, according to results of a systemic review and network meta-analysis.

The Ministry of Food and Drug Safety in South Korea has granted regulatory approval for Vyzulta, according to a press release from Bausch Health.

Two IOP reduction methods from Glaukos showed favorable results and safety profiles in recent trials, according to company press releases.

The European Commission has granted marketing authorization for Roclanda to reduce IOP in adults with primary open-angle glaucoma or ocular hypertension, according to a press release from Aerie Pharmaceuticals.

Choroidal microvasculature dropout angular circumference increases were significantly associated with visual field progression among patients with open-angle glaucoma, according to results published in the American Journal of Ophthalmology.

An automated direct transscleral selective laser trabeculoplasty device demonstrated safety and efficacy in a first-in-human study, Michal Belkin, MD, said in a presentation at the virtual American Academy of Ophthalmology annual meeting.

In this Healio Video Perspective from the virtual AAO annual meeting, Michael R. Robinson, MD, discusses patient characteristics affecting long-term IOP-lowering effects after implantation of Durysta (bimatoprost implant, AbbVie).

During a most unexpected and challenging year, ophthalmic practices are looking for reasons to celebrate.